Management of Post-Facelift Facial Paralysis With Botulinum Toxin Type A.
Abstract
[BACKGROUND] Facial nerve injury after facelift is rare; hence, its treatment is poorly established. Botulinum toxin type A (BTXA) can be employed to resolve the asymmetry. To our knowledge, there is no protocol in the literature about the best timing for this treatment, injection sites, or recommended dose.
[OBJECTIVES] The authors sought to propose a protocol to guide the management of asymmetries post-facelift.
[METHODS] Fifteen patients with post-rhytidectomy facial palsies were treated in the non-paralyzed side with BTXA. After analysis of the smile deviation vectors, it is possible to identify the muscles that should be treated. The dose varied from 1 to 2 volume-unit per point. Patients were examined after 15 days for outcomes evaluation and touch-up if needed. Patients were re-treated after 5 to 6 months in case of asymmetry recurrence.
[RESULTS] Symmetry was achieved in all cases. Six patients had definitive nerve lesions and required treatment every 6 months after the first session. Five patients had lesions affecting the upper third of the face; 4 of them were definitive nerve lesions. Two of the 4 patients who were treated less than 2 weeks after surgery recovered early from the post-facelift paralysis and developed reversed asymmetry due to the BTXA. In 7 patients, the post-facelift asymmetry was due to neuropraxis: the recovery from the nerve injury and BTXA treatment occurred symmetrically on both sides of the face in the following months after 1 single session.
[CONCLUSIONS] Asymmetries post-facelift were successfully managed with the proposed protocol. The best time for injection was 2 to 4 weeks after surgery.
[OBJECTIVES] The authors sought to propose a protocol to guide the management of asymmetries post-facelift.
[METHODS] Fifteen patients with post-rhytidectomy facial palsies were treated in the non-paralyzed side with BTXA. After analysis of the smile deviation vectors, it is possible to identify the muscles that should be treated. The dose varied from 1 to 2 volume-unit per point. Patients were examined after 15 days for outcomes evaluation and touch-up if needed. Patients were re-treated after 5 to 6 months in case of asymmetry recurrence.
[RESULTS] Symmetry was achieved in all cases. Six patients had definitive nerve lesions and required treatment every 6 months after the first session. Five patients had lesions affecting the upper third of the face; 4 of them were definitive nerve lesions. Two of the 4 patients who were treated less than 2 weeks after surgery recovered early from the post-facelift paralysis and developed reversed asymmetry due to the BTXA. In 7 patients, the post-facelift asymmetry was due to neuropraxis: the recovery from the nerve injury and BTXA treatment occurred symmetrically on both sides of the face in the following months after 1 single session.
[CONCLUSIONS] Asymmetries post-facelift were successfully managed with the proposed protocol. The best time for injection was 2 to 4 weeks after surgery.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | facelift
|
안면거상술 | dict | 6 | |
| 합병증 | asymmetry
|
비대칭 | dict | 4 | |
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 2 | |
| 시술 | rhytidectomy
|
안면거상술 | dict | 1 | |
| 해부 | muscles
|
scispacy | 1 | ||
| 해부 | nerve
|
scispacy | 1 | ||
| 합병증 | nerve lesions
|
scispacy | 1 | ||
| 합병증 | lesions
|
scispacy | 1 | ||
| 약물 | [BACKGROUND] Facial nerve
|
scispacy | 1 | ||
| 약물 | [OBJECTIVES]
|
scispacy | 1 | ||
| 약물 | [RESULTS]
|
scispacy | 1 | ||
| 약물 | post-facelift
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS] Asymmetries
|
scispacy | 1 | ||
| 질환 | nerve injury
|
C0161479
Nerve injury
|
scispacy | 1 | |
| 질환 | post-rhytidectomy facial palsies
|
scispacy | 1 | ||
| 질환 | nerve lesions
|
C0847483
nerve lesion
|
scispacy | 1 | |
| 질환 | paralysis
|
C0522224
Paralysed
|
scispacy | 1 | |
| 기타 | Post-Facelift Facial
|
scispacy | 1 | ||
| 기타 | Botulinum Toxin Type A.
|
scispacy | 1 | ||
| 기타 | BTXA
→ Botulinum toxin type A
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | post-facelift
|
scispacy | 1 |
MeSH Terms
Botulinum Toxins, Type A; Face; Facial Expression; Facial Muscles; Facial Paralysis; Humans; Neuromuscular Agents; Rhytidoplasty
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.